Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M D Abeloff

Showing results (81-90 of 90) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 90 results.
Journal of the National Cancer Institute|April 4, 1990
Sixteen-week dose-intense chemotherapy in the adjuvant treatment of breast cancerM D Abeloff, R A Beveridge, R C Donehower, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1996
Adjuvant CMFVP versus adjuvant CMFVP plus ovariectomy for premenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group studyS E Rivkin, S Green, J O'Sullivan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1993
Phase II study of goserelin for patients with postmenopausal metastatic breast cancerT Saphner, A B Troxel, D C Tormey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1994
Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group studyS E Rivkin, S Green, B Metch, et al.
Journal of the National Cancer Institute. Monographs|January 1, 1992
Prognostic potential of DNA flow cytometry measurements in node-negative breast cancer patients: preliminary analysis of an intergroup study (INT 0076)L G Dressler, L Eudey, R Gray, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1990
High-dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin's diseaseR J Jones, S Piantadosi, R B Mann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1992
Prognostic significance of S-phase fraction in good-risk, node-negative breast cancer patientsG M Clark, M C Mathieu, M A Owens, et al.
Cancer Research|August 1, 1990
Phase I and pharmacokinetic study of brequinar sodium (NSC 368390)D A Noe, E K Rowinsky, H S Shen, et al.
Journal of the National Cancer Institute|February 22, 2001
Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesisR Bos, H Zhong, C F Hanrahan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 1998
Sixteen-week multidrug regimen versus cyclophosphamide, doxorubicin, and fluorouracil as adjuvant therapy for node-positive, receptor-negative breast cancer: an Intergroup studyJ H Fetting, R Gray, D L Fairclough, et al.
Pageof 9

Showing results (81-90 of 90) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 90 results.
Journal of the National Cancer Institute|April 4, 1990
Sixteen-week dose-intense chemotherapy in the adjuvant treatment of breast cancerM D Abeloff, R A Beveridge, R C Donehower, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1996
Adjuvant CMFVP versus adjuvant CMFVP plus ovariectomy for premenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group studyS E Rivkin, S Green, J O'Sullivan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1993
Phase II study of goserelin for patients with postmenopausal metastatic breast cancerT Saphner, A B Troxel, D C Tormey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1994
Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group studyS E Rivkin, S Green, B Metch, et al.
Journal of the National Cancer Institute. Monographs|January 1, 1992
Prognostic potential of DNA flow cytometry measurements in node-negative breast cancer patients: preliminary analysis of an intergroup study (INT 0076)L G Dressler, L Eudey, R Gray, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1990
High-dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin's diseaseR J Jones, S Piantadosi, R B Mann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1992
Prognostic significance of S-phase fraction in good-risk, node-negative breast cancer patientsG M Clark, M C Mathieu, M A Owens, et al.
Cancer Research|August 1, 1990
Phase I and pharmacokinetic study of brequinar sodium (NSC 368390)D A Noe, E K Rowinsky, H S Shen, et al.
Journal of the National Cancer Institute|February 22, 2001
Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesisR Bos, H Zhong, C F Hanrahan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 1998
Sixteen-week multidrug regimen versus cyclophosphamide, doxorubicin, and fluorouracil as adjuvant therapy for node-positive, receptor-negative breast cancer: an Intergroup studyJ H Fetting, R Gray, D L Fairclough, et al.
Pageof 9